Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of July 7, 2025 • 11:31 PM ET

Date/Time Source News Release
07/02/2025 02:00 AM EDT GlobeNewswire OSE Immunotherapeutics met à jour l'information sur les procédures en cours
06/30/2025 12:00 PM EDT GlobeNewswire OSE Immunotherapeutics Publishes Letter to Shareholders
06/25/2025 02:00 AM EDT GlobeNewswire OSE Immunotherapeutics provides an update on ongoing proceedings
06/20/2025 01:30 PM EDT GlobeNewswire OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
06/11/2025 12:30 PM EDT GlobeNewswire ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
06/09/2025 02:00 AM EDT GlobeNewswire UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
06/04/2025 02:00 AM EDT GlobeNewswire OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
06/02/2025 12:00 PM EDT GlobeNewswire OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer
05/23/2025 01:00 AM EDT GlobeNewswire OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRP? Blockade in Two Ongoing Trials at ASCO 2025
05/05/2025 12:30 PM EDT GlobeNewswire OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
Page

Additional News

As of July 7, 2025 • 11:31 PM ET

Date/Time Source News Release
09/23/2022 01:41 AM EDT SeekingAlpha OSE Immunotherapeutics SA GAAP EPS of -Euro0.11, revenue of Euro16.05M
05/27/2021 04:09 PM EDT SeekingAlpha Phase 2 trials begin of OSE's vaccine with Bristol's Opdivo in NSCLC
03/26/2021 02:05 PM EDT SeekingAlpha OSE Immunotherapeutics SA reports FY results
01/18/2021 10:22 AM EST SeekingAlpha Trillium Therapeutics: A Potentially Undervalued CD47 Player
10/05/2018 01:23 PM EDT SeekingAlpha OSE Immunotherapeutics Presents At 18th Annual Biotech in Europe Investor Forum - Slideshow
09/06/2018 12:07 PM EDT SeekingAlpha OSE Immunotherapeutics reports 1H results
07/03/2018 12:00 PM EDT SeekingAlpha Targeting CD47: To Eat Or Not To Eat?
03/28/2018 12:09 PM EDT SeekingAlpha OSE Immunotherapeutics reports FY results
Page
  • 1